Validation of a semiconductor next-generation sequencing assay for the clinical genetic screening of cftr

Molecular Genetics and Genomic Medicine

Volumn 3, Issue 5, 2015, Pages 396-403

  Trujillano, Daniel ^a   Weiss, Maximilian E R ^a   Köster, Julia ^a   Papachristos, Efstathios B ^a   Werber, Martin ^a   Kandaswamy, Krishna Kumar ^a   Marais, Anett ^a   Eichler, Sabrina ^a   Creed, Jenny ^a   Baysal, Erol ^b   Jaber, Iqbal Yousuf ^b   Mehaney, Dina Ahmed ^c   Farra, Chantal ^d   Rolfs, Arndt ^a,e  

^a CENTOGENE AG   (Germany)

^b DUBAI HEALTH AUTHORITY   (United Arab Emirates)

^c CAIRO UNIVERSITY   (Egypt)

^d AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^e UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

CFTR; Cystic fibrosis; Ion Torrent; Molecular diagnostics; Next generation sequencing; Validation

Indexed keywords

EID: 84960501554     PISSN: None     EISSN: 23249269     Source Type: Journal    
DOI: 10.1002/mgg3.149     Document Type: Article

References (21)

1. Bobadilla, J. L., M. Macek, J. P. Fine, and P. M. Farrell. 2002. Cystic fibrosis: a worldwide analysis of CFTR mutations– correlation with incidence data and application to screening. Hum. Mutat. 19:575–606.
2. Chan, M., S. M. Ji, Z. X. Yeo, L. Gan, E. Yap, Y. S. Yap, et al. 2012. Development of a next-generation sequencing method for BRCA mutation screening: a comparison between a high-throughput and a benchtop platform. J. Mol. Diagn. 14:602–612.
3. Chen, N., and A. E. Prada. 2014. Development of allele-specific multiplex PCR to determine the length of poly-T in intron 8 of CFTR. PeerJ 2:e468.
4. Dequeker, E., M. Stuhrmann, M. A. Morris, T. Casals, C. Castellani, M. Claustres, et al. 2009. Best practice guidelines for molecular genetic diagnosis of cystic fibrosis and CFTR-related disorders–updated European recommendations. Eur. J. Hum. Genet. 17:51–65.
5. Estivill, X., C. Bancells, and C. Ramos. 1997. Geographic distribution and regional origin of 272 cystic fibrosis mutations in European populations. The biomed CF mutation analysis consortium. Hum. Mutat. 10:135–154.
6. Farrell, P. M. 2008. The prevalence of cystic fibrosis in the European Union. J. Cyst. Fibros. 7:450–453.
7. Grosu, D. S., L. Hague, M. Chelliserry, K. M. Kruglyak, R. Lenta, B. Klotzle, et al. 2014. Clinical investigational studies for validation of a next-generation sequencing in vitro diagnostic device for cystic fibrosis testing. Expert Rev. Mol. Diagn. 14:605–622.
8. Kerem, B., J. M. Rommens, J. A. Buchanan, D. Markiewicz, T. K. Cox, A. Chakravarti, et al. 1989. Identification of the cystic fibrosis gene: genetic analysis. Science 245:1073–1080.
9. Mattocks, C. J., M. A. Morris, G. Matthijs, E. Swinnen, A. Corveleyn, E. Dequeker, et al. 2010. A standardized framework for the validation and verification of clinical molecular genetic tests. Eur. J. Hum. Genet. 18:1276–1288.
10. Nakano, E., A. Masamune, T. Niihori, K. Kume, S. Hamada, Y. Aoki, et al. 2014. Targeted next-generation sequencing effectively analyzed the cystic fibrosis transmembrane conductance regulator gene in pancreatitis. Dig. Dis. Sci. [Epub ahead of print].
11. Newcombe, R. G. 1998. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat. Med. 17:857–872.
12. O’Sullivan, B. P., and S. D. Freedman. 2009. Cystic fibrosis. Lancet 373:1891–1904.
13. Riordan, J. R., J. M. Rommens, B. Kerem, N. Alon, R. Rozmahel, Z. Grzelczak, et al. 1989. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245:1066–1073.
14. Robinson, J. T., H. Thorvaldsdñottir, W. Winckler, M. Guttman, E. S. Lander, G. Getz, et al. 2011. Integrative genomics viewer. Nat. Biotechnol. 29:24–26.
15. Rommens, J. M., M. C. Iannuzzi, B. Kerem, M. L. Drumm, G. Melmer, M. Dean, et al. 1989. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 245:1059–1065.
16. Tavtigian, S. V., A. M. Deffenbaugh, L. Yin, T. Judkins, T. Scholl, P. B. Samollow, et al. 2006. Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral. J. Med. Genet. 43:295–305.
17. Trujillano, D., M. D. Ramos, J. Gonzñalez, C. Tornador, F. Sotillo, G. Escaramis, et al. 2013. Next generation diagnostics of cystic fibrosis and CFTR-related disorders by targeted multiplex high-coverage resequencing of CFTR. J. Med. Genet. 50:455–462.
18. Walsh, T., M. K. Lee, S. Casadei, A. M. Thornton, S. M. Stray, C. Pennil, et al. 2010. Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc. Natl. Acad. Sci. USA 107:12629–12633.
19. Wang, K., M. Li, and H. Hakonarson. 2010. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38: e164.
20. Watson, M. S., G. R. Cutting, R. J. Desnick, D. A. Driscoll, K. Klinger, M. Mennuti, et al. 2004. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. Genet. Med. 6:387–391.
21. Whitcomb, D. C. 2012. Framework for interpretation of genetic variations in pancreatitis patients. Front. Physiol. 3:440.